505 results on '"Onal, Cem"'
Search Results
2. Long-term analysis of hematological parameters as predictors of recurrence patterns and treatment outcomes in cervical cancer patients undergoing definitive chemoradiotherapy
3. Letter to the editor concerning ‘Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis.’
4. Letter to the editor regarding ‘SBRT‑SG‑01: final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases’
5. The significance of metabolic response to neoadjuvant androgen deprivation therapy detected with [68Ga]Ga-PSMA-11-PET/CT in high-risk prostate cancer patients treated with definitive radiotherapy
6. Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate Cancer
7. Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study
8. In Regard to Ong et al.
9. The impact of the apparent diffusion coefficient for the early prediction of the treatment response after definitive radiotherapy in prostate cancer patients
10. Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study
11. Contralateral breast radiation doses in breast cancer patients treated with helical tomotherapy
12. The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma
13. Evaluation of Treatment Outcomes of Prostate Cancer Patients With Lymph Node Metastasis Treated With Definitive Radiotherapy
14. Patterns of failure after prostate-only radiotherapy in high-risk prostate cancer: Implications for refining pelvic nodal contouring guidelines In regard to Singh et al.
15. Prostate-specific membrane antigen PET response associates with metastasis-free survival following stereotactic ablative radiation in oligometastatic prostate cancer
16. Significance of liver metastasis volume in breast cancer patients treated with stereotactic body radiotherapy
17. Stereotactic radiotherapy to oligoprogressive lesions detected with 68Ga-PSMA-PET/CT in castration-resistant prostate cancer patients
18. Preface
19. The effect of dose‐escalation radiotherapy with simultaneous‐integrated‐boost on the use of short‐term androgen deprivation therapy in patients with intermediate risk prostate cancer
20. Dosimetric evaluation of ultrafractionated dose escalation with simultaneous integrated boost to intraprostatic lesion using 1.5-Tesla MR-Linac in localized prostate cancer
21. Re: Pawel Rajwa, Daniele Robesti, Michael Chaloupka, et al. Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.006
22. Can nomograms accurately predict lymph node metastasis in high-risk prostate cancer patients receiving definitive radiotherapy in the PSMA-PET/CT era?—Time to burry the hatchet
23. A Comparative Analysis of Implant-sparing PlanVersusConventional Plans Utilizing Helical Tomotherapy in Breast Cancer Patients Undergoing Breast Reconstruction
24. Treatment Outcomes of External Beam Radiotherapy with or Without Focal Boost to Intraprostatic Lesions in Patients with Localized Prostate Cancer
25. The Effect of Age on Clinicopathological Features and Treatment Outcomes of Patients Receiving Definitive Radiotherapy for Localized Prostate Cancer
26. The potential role of MR-guided adaptive radiotherapy in pediatric oncology: Results from a SIOPE-COG survey
27. Oncological outcomes of squamous cell carcinoma of the cervical esophagus treated with definitive (chemo‑)radiotherapy: a systematic review and meta‑analysis. In regard to De Virgilio et al
28. Longer treatment time and lower radiation doses—an alternative for Graves’ ophthalmopathy treatment
29. The use of 18F-FDG positron emission tomography to detect mediastinal lymph nodes in metastatic breast cancer
30. A Comparative Analysis of Implant-sparing Plan Versus Conventional Plans Utilizing Helical Tomotherapy in Breast Cancer Patients Undergoing Breast Reconstruction.
31. Genitourinary System Cancers
32. Long-term assessment of clinical parameters and positron emission tomography parameters in predicting recurrence in uterine cervical cancer patients receiving definitive chemoradiotherapy
33. The impact of margin reduction on radiation dose distribution of ultra‐hypofractionated prostate radiotherapy utilizing a 1.5‐T MR‐Linac
34. Letter to the editor regarding ‘Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY‑2 clinical trial subanalysis’
35. A Liquid Chromatographic Analysis of Deferasirox in Human Breast Milk with Fluorimetric Detection
36. Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002)
37. Radiotherapy After Skin-Sparing Mastectomy and Implant-Based Breast Reconstruction
38. Incidental testicular doses during volumetric-modulated arc radiotherapy in prostate cancer patients
39. Retrospective correlation of 68ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy
40. The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients
41. Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate
42. Treatment outcomes of prostate cancer patients with Gleason score 8–10 treated with definitive radiotherapy: TROD 09-001 multi-institutional study
43. Upfront metastasis‑directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance: in regard to Triggiani et al.
44. Partially Ablative Body Radiotherapy (PABR): A novel approach for palliative radiotherapy of locally advanced bulky unresectable sarcomas. In regard to Yu et al.
45. Primary extranodal lymphoma of the glands. Literature review and options for best practice in 2019
46. Dosimetric comparison of vaginal vault brachytherapy vs applicator-guided stereotactic body radiotherapy with volumetric modulated arc therapy and helical tomotherapy for endometrium cancer patients
47. Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy
48. Local recurrence outcomes after breast conserving surgery and adjuvant radiotherapy in ductal carcinoma in situ of the breast and a comparison with ECOG E5194 study
49. Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy. In regard to Vojtíšek et al.
50. Long-term assessment of clinical parameters and positron emission tomography parameters in predicting recurrence in uterine cervical cancer patients receiving definitive chemoradiotherapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.